𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration

✍ Scribed by Norbert Stute; William E. Evans; Wayne I. Furman; Michael Schell


Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
703 KB
Volume
84
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Recombinant human granulocyte-macrophage
✍ Saarinen, Ulla M. ;Hovi, Liisa ;Riikonen, Pekka ;Pihkala, Jaana ;Juvonen, Eeva πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 721 KB

## Abstract Twenty children 1–17 (median, 5.5) years of age received GM‐CSF during chemotherapy‐induced neutropenia at the dose of 5 ΞΌg/kg/day, continued until the absolute neutrophil count (ANC) exceeded 500 Γ— 10^6^/liter. Twelve children with solid tumors received GM‐CSF after courses of conventi

Recombinant human granulocyte-colony sti
✍ Hal E. Broxmeyer; Douglas E. Williams; Scott Cooper; Giao Hangoc; Peter Ralph πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 579 KB

Combinations of low dosages of purified recombinant human (rh) macrophagecolony stimulating factor (M-CSF; also termed CSF-1) and rh granulocyte-colony stimulating factor (G-CSF) were compared alone and in combination for their influence on the cycling rates and numbers of bone marrow and splenic gr

Pilot study of recombinant human granulo
✍ Julio Martin; Orencio Bosch; Gloria Moraleda; Javier Bartolome; Juan Antonio Qui πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 593 KB

is a fellow of Ministerio de Educaci6n y Ciencia. J. Bartolome and J.A. Quiroga are recipients of research grants from Fundacion para el Estudio de las Hepatitis Vudes.

Recombinant human granulocyte macrophage
✍ Dr A. M. Oza; M. Leahy; E. Dorey; C. L. Davis; J. Amess; M. Horton; A. Z. S. Roh πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 613 KB

Fourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and adriamycin administered on days 1-8.